Acelyrin Inc (SLRN)
4.68
-0.20
(-4.10%)
USD |
NASDAQ |
May 10, 16:00
4.91
+0.23
(+4.91%)
After-Hours: 20:00
Acelyrin Total Liabilities (Quarterly): 86.35M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 86.35M |
| September 30, 2023 | 68.11M |
| June 30, 2023 | 34.06M |
| Date | Value |
|---|---|
| March 31, 2023 | 441.87M |
| December 31, 2022 | 422.78M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
34.06M
Minimum
Jun 2023
441.87M
Maximum
Mar 2023
210.64M
Average
86.35M
Median
Dec 2023
Total Liabilities (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | 128.35M |
| Eagle Pharmaceuticals Inc | 152.78M |
| Avalo Therapeutics Inc | 13.69M |
| Design Therapeutics Inc | 11.96M |
| CEL-SCI Corp | 16.06M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 742.69M |
| Shareholders Equity (Quarterly) | 656.34M |